Stallergenes Greer PLC: Daniel Smith Appointed Global Head of Information Technology

Regulatory News:

Stallergenes Greer plc (the "Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced the appointment of Daniel Smith as Global Head of Information Technology.

Daniel has more than 20 years of international experience in Information Technology with extensive expertise in the pharmaceutical industry. He joins Stallergenes Greer after six years at Zoetis, Inc. formerly Pfizer Pharmaceuticals International where he was responsible for driving innovation in global infrastructure business technology programs, including pharma-focused enterprise resource planning (ERP) systems, digital e-commerce, and sales force support platforms. The ERP systems included a comprehensive change management implementation covering over 27 countries supporting thousands of users in the operations and manufacturing.

Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer, said:

"I am pleased to welcome Daniel as our Global Head of Information Technology. He will play a vital role in overseeing large scale implementations and upgrades across the business, such as the continuation of the ERP rollout, while standardizing technology globally. Daniel will be responsible for developing a long-term strategic IT plan, ensuring the implementation of a best-in-class and consistent IT framework for our commercial, manufacturing and quality functions.”

ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification 4577
Market: Euronext Paris regulated market

Additional information is available at http://www.stallergenesgreer.com

This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160411005440/en/